RxDoctor Payments DataLook up a doctor →

Lee Schwartzberg, MD

Medical Oncology · Reno, NVNPI 1306878228

Payments from drug & device makers

$6,717,805in general payments, 2019–2025

Across 1,017 payments — averaging $6605.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$2.7M
  • Pfizer$1.5M
  • Merck$638K
  • Genentech, Inc.$526K
  • AstraZeneca$195K
  • Daiichi Sankyo Inc.$143K
  • plus $939K from 51 others
$69,515in research payments, 2019–2025

Across 37 payments — averaging $1878.80 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$32K
  • F. Hoffmann-la Roche AG$17K
  • Eli Lilly$9K
  • Pfizer$8K
  • Amgen$3K
  • Hoffmann-la Roche Limited$125

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis83$2,738,910
Pfizer(2 entities)167$1,537,207
Merck39$638,158
Genentech, Inc.92$526,394
AstraZeneca(2 entities)105$195,293
Daiichi Sankyo Inc.132$143,003
Cornerstone Specialty Network LLC22$113,661
E.r. Squibb & Sons, L.L.C.23$103,238
Puma Biotechnology, Inc.29$83,999
Spectrum Pharmaceuticals Inc.26$78,032
Napo Pharmaceuticals Inc31$62,735
Chugai Pharmaceutical Co., Ltd.7$59,495
AbbVie21$55,678
Coherus Oncology, Inc.16$52,839
GSK10$49,409
Seagen Inc.28$44,206
Gilead(2 entities)18$34,879
Immunomedics, Inc.11$23,080
Veru Inc.4$22,393
Amgen11$19,130
Helsinn Healthcare SA12$18,850
Bayer15$18,489
Eli Lilly21$14,492
Genentech USA, Inc.11$12,163
Lilly USA, LLC10$11,869
Astrazeneca UK Limited4$10,275
Medivation LLC.6$7,482
Foundation Medicine, Inc.4$6,699
Sandoz1$5,895
Siemens Medical Solutions USA, Inc.6$5,725
Tesaro, Inc.6$5,252
Helsinn Therapeutics (U.S.), Inc.1$4,125
Sanofi4$3,666
Athenex Pharmaceutical Division, LLC1$3,000
Fresenius Kabi USA, LLC1$1,800
Stemline Therapeutics Inc.3$1,638
Myriad Genetic Laboratories, Inc.1$1,400
F. Hoffmann-la Roche AG2$1,031
Eisai Inc.1$938
Sun Pharmaceutical Industries Inc.3$233
Beigene USA, Inc.1$133
Johnson & Johnson5$132
Regeneron Healthcare Solutions, Inc.1$120
Blueprint Medicines Corporation1$117
Astellas Pharma US Inc4$89
Incyte Corporation3$81
Sanofi-aventis U.S. LLC2$58
Array Biopharma Inc2$56
Sobi, Inc1$48
Ipsen Biopharmaceuticals, Inc2$47
Beone Medicines USA, Inc.1$32
Genmab U.S., Inc.1$25
Bristol Myers Squibb1$25
ADMA Biomanufacturing LLC1$24
Tersera Therapeutics LLC1$21
Takeda Pharmaceuticals U.S.A., Inc.1$19
Aimmune Therapeutics, Inc.1$19

How this compares

Too few medical oncology providers in Nevadato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$36,529
Medicare patients
154
Services billed
383

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other medical oncology in Reno

See the full list for Nevada →

Where these figures come from

Is this you, or does something look wrong? →